Financhill
Sell
41

GH Quote, Financials, Valuation and Earnings

Last price:
$30.43
Seasonality move :
10%
Day range:
$30.14 - $31.38
52-week range:
$15.81 - $38.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
5.34x
P/B ratio:
28.68x
Volume:
1.2M
Avg. volume:
1.7M
1-year change:
8.64%
Market cap:
$3.8B
Revenue:
$563.9M
EPS (TTM):
-$4.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GH
Guardant Health
$170.6M -$0.60 20.53% -67% $42.30
DCTH
Delcath Systems
$10.5M -$0.19 2204.21% -93.94% --
DGX
Quest Diagnostics
$2.4B $2.26 12.75% 28.89% $169.96
EXAS
Exact Sciences
$717M -$0.10 8.59% -18.18% $71.86
NTRA
Natera
$361.1M -$0.59 31.98% -22.45% $167.90
PGNY
Progyny
$297.4M $0.37 2.66% 183.52% $30.22
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GH
Guardant Health
$30.44 $42.30 $3.8B -- $0.00 0% 5.34x
DCTH
Delcath Systems
$11.96 -- $382.4M -- $0.00 0% 14.33x
DGX
Quest Diagnostics
$152.63 $169.96 $17B 20.51x $0.75 1.94% 1.80x
EXAS
Exact Sciences
$57.55 $71.86 $10.7B -- $0.00 0% 3.91x
NTRA
Natera
$159.64 $167.90 $21.1B -- $0.00 0% 12.68x
PGNY
Progyny
$14.71 $30.22 $1.3B 25.36x $0.00 0% 1.27x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GH
Guardant Health
105.56% 4.729 40.42% 5.51x
DCTH
Delcath Systems
18.92% 0.853 0.79% 0.97x
DGX
Quest Diagnostics
47.86% -0.146 35.62% 1.02x
EXAS
Exact Sciences
44.45% -0.061 20.38% 1.78x
NTRA
Natera
29.47% 3.271 2.33% 4.08x
PGNY
Progyny
-- 1.563 -- 2.48x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GH
Guardant Health
$117M -$117.3M -42.02% -651% -55.92% -$55.3M
DCTH
Delcath Systems
$9.6M -$1.3M -167.55% -251.36% -11.24% -$3.9M
DGX
Quest Diagnostics
$811M $330M 7.3% 12.68% 14.23% $250M
EXAS
Exact Sciences
$512.6M -$20.8M -3.82% -6.77% -4.11% $112.6M
NTRA
Natera
$271.7M -$39.3M -18.26% -26.45% -6.3% $25M
PGNY
Progyny
$59.2M $12.5M 11.31% 11.31% 4.35% $42.7M

Guardant Health vs. Competitors

  • Which has Higher Returns GH or DCTH?

    Delcath Systems has a net margin of -56.28% compared to Guardant Health's net margin of 16.64%. Guardant Health's return on equity of -651% beat Delcath Systems's return on equity of -251.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health
    61.1% -$0.88 $1.1B
    DCTH
    Delcath Systems
    85.36% $0.06 $10.6M
  • What do Analysts Say About GH or DCTH?

    Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 41.92%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 78.37%. Given that Delcath Systems has higher upside potential than Guardant Health, analysts believe Delcath Systems is more attractive than Guardant Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health
    14 1 0
    DCTH
    Delcath Systems
    0 0 0
  • Is GH or DCTH More Risky?

    Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

  • Which is a Better Dividend Stock GH or DCTH?

    Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or DCTH?

    Guardant Health quarterly revenues are $191.5M, which are larger than Delcath Systems quarterly revenues of $11.2M. Guardant Health's net income of -$107.8M is lower than Delcath Systems's net income of $1.9M. Notably, Guardant Health's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.34x versus 14.33x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health
    5.34x -- $191.5M -$107.8M
    DCTH
    Delcath Systems
    14.33x -- $11.2M $1.9M
  • Which has Higher Returns GH or DGX?

    Quest Diagnostics has a net margin of -56.28% compared to Guardant Health's net margin of 9.08%. Guardant Health's return on equity of -651% beat Quest Diagnostics's return on equity of 12.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health
    61.1% -$0.88 $1.1B
    DGX
    Quest Diagnostics
    32.6% $1.99 $13.2B
  • What do Analysts Say About GH or DGX?

    Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 41.92%. On the other hand Quest Diagnostics has an analysts' consensus of $169.96 which suggests that it could grow by 11.35%. Given that Guardant Health has higher upside potential than Quest Diagnostics, analysts believe Guardant Health is more attractive than Quest Diagnostics.

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health
    14 1 0
    DGX
    Quest Diagnostics
    8 9 0
  • Is GH or DGX More Risky?

    Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Quest Diagnostics has a beta of 0.893, suggesting its less volatile than the S&P 500 by 10.74%.

  • Which is a Better Dividend Stock GH or DGX?

    Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics offers a yield of 1.94% to investors and pays a quarterly dividend of $0.75 per share. Guardant Health pays -- of its earnings as a dividend. Quest Diagnostics pays out 36.77% of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GH or DGX?

    Guardant Health quarterly revenues are $191.5M, which are smaller than Quest Diagnostics quarterly revenues of $2.5B. Guardant Health's net income of -$107.8M is lower than Quest Diagnostics's net income of $226M. Notably, Guardant Health's price-to-earnings ratio is -- while Quest Diagnostics's PE ratio is 20.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.34x versus 1.80x for Quest Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health
    5.34x -- $191.5M -$107.8M
    DGX
    Quest Diagnostics
    1.80x 20.51x $2.5B $226M
  • Which has Higher Returns GH or EXAS?

    Exact Sciences has a net margin of -56.28% compared to Guardant Health's net margin of -5.4%. Guardant Health's return on equity of -651% beat Exact Sciences's return on equity of -6.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health
    61.1% -$0.88 $1.1B
    EXAS
    Exact Sciences
    72.33% -$0.21 $5.8B
  • What do Analysts Say About GH or EXAS?

    Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 41.92%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 24.86%. Given that Guardant Health has higher upside potential than Exact Sciences, analysts believe Guardant Health is more attractive than Exact Sciences.

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health
    14 1 0
    EXAS
    Exact Sciences
    17 3 0
  • Is GH or EXAS More Risky?

    Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

  • Which is a Better Dividend Stock GH or EXAS?

    Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or EXAS?

    Guardant Health quarterly revenues are $191.5M, which are smaller than Exact Sciences quarterly revenues of $708.7M. Guardant Health's net income of -$107.8M is lower than Exact Sciences's net income of -$38.2M. Notably, Guardant Health's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.34x versus 3.91x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health
    5.34x -- $191.5M -$107.8M
    EXAS
    Exact Sciences
    3.91x -- $708.7M -$38.2M
  • Which has Higher Returns GH or NTRA?

    Natera has a net margin of -56.28% compared to Guardant Health's net margin of -7.18%. Guardant Health's return on equity of -651% beat Natera's return on equity of -26.45%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health
    61.1% -$0.88 $1.1B
    NTRA
    Natera
    61.8% -$0.26 $1.2B
  • What do Analysts Say About GH or NTRA?

    Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 41.92%. On the other hand Natera has an analysts' consensus of $167.90 which suggests that it could grow by 5.17%. Given that Guardant Health has higher upside potential than Natera, analysts believe Guardant Health is more attractive than Natera.

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health
    14 1 0
    NTRA
    Natera
    12 0 0
  • Is GH or NTRA More Risky?

    Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Natera has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.789%.

  • Which is a Better Dividend Stock GH or NTRA?

    Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Natera pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or NTRA?

    Guardant Health quarterly revenues are $191.5M, which are smaller than Natera quarterly revenues of $439.8M. Guardant Health's net income of -$107.8M is lower than Natera's net income of -$31.6M. Notably, Guardant Health's price-to-earnings ratio is -- while Natera's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.34x versus 12.68x for Natera. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health
    5.34x -- $191.5M -$107.8M
    NTRA
    Natera
    12.68x -- $439.8M -$31.6M
  • Which has Higher Returns GH or PGNY?

    Progyny has a net margin of -56.28% compared to Guardant Health's net margin of 3.64%. Guardant Health's return on equity of -651% beat Progyny's return on equity of 11.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    GH
    Guardant Health
    61.1% -$0.88 $1.1B
    PGNY
    Progyny
    20.67% $0.11 $434.9M
  • What do Analysts Say About GH or PGNY?

    Guardant Health has a consensus price target of $42.30, signalling upside risk potential of 41.92%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 28.19%. Given that Guardant Health has higher upside potential than Progyny, analysts believe Guardant Health is more attractive than Progyny.

    Company Buy Ratings Hold Ratings Sell Ratings
    GH
    Guardant Health
    14 1 0
    PGNY
    Progyny
    4 4 0
  • Is GH or PGNY More Risky?

    Guardant Health has a beta of 1.255, which suggesting that the stock is 25.526% more volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

  • Which is a Better Dividend Stock GH or PGNY?

    Guardant Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GH or PGNY?

    Guardant Health quarterly revenues are $191.5M, which are smaller than Progyny quarterly revenues of $286.6M. Guardant Health's net income of -$107.8M is lower than Progyny's net income of $10.4M. Notably, Guardant Health's price-to-earnings ratio is -- while Progyny's PE ratio is 25.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health is 5.34x versus 1.27x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GH
    Guardant Health
    5.34x -- $191.5M -$107.8M
    PGNY
    Progyny
    1.27x 25.36x $286.6M $10.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Uber Stock a Buy on the Dip?
Is Uber Stock a Buy on the Dip?

Shares of Uber Technologies (NYSE:UBER) have been fading fast in…

Is AMD Stock an All-Time Buy?
Is AMD Stock an All-Time Buy?

Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…

How High Will Airbnb Stock Go?
How High Will Airbnb Stock Go?

Airbnb, Inc. (NASDAQ:ABNB) share price has seen substantial turbulence over…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
54
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Alerts

Sell
50
LMND alert for Dec 28

Lemonade [LMND] is down 10.69% over the past day.

Sell
50
TSLL alert for Dec 28

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.

Buy
63
SMLR alert for Dec 28

Semler Scientific [SMLR] is down 9.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock